Beyond Clinical Toxicity: Repositioning the Truelove and Witts Criteria in the Treat-to-Target Era of Acute Severe Ulcerative Colitis

Ulcerative colitis affects millions of people worldwide, and acute severe ulcerative colitis (ASUC) remains one of its most urgent presentations because delayed recognition of steroid non-response can expose patients to colectomy, postoperative complications, and prolonged hospitalization. The Truelove and Witts (T&W) criteria, first published in 1955, remain historically important because they provide a simple bedside definition of severe disease and continue to inform admission thresholds in contemporary practice. This opinion article argues that the T&W criteria should be retained as an entry definition for classic ASUC but should no longer be used as a standalone framework for dynamic risk stratification or treatment escalation. Modern guidelines and consensus statements increasingly supplement clinical toxicity with C-reactive protein (CRP), albumin, fecal calprotectin, validated endoscopic scores, intestinal ultrasound, and early prognostic indices. These tools do not replace bedside assessment; rather, they help clinicians identify steroid non-response and inflammatory burden before systemic toxicity alone becomes decisive. A balanced interpretation is therefore required: the T&W criteria remain useful because they are simple, familiar, and globally applicable, but they are insufficient by themselves for treat-to-target decision-making. Future ASUC severity classifications should integrate traditional clinical assessment with objective biomarkers, endoscopic findings, imaging, and prospective validation across both resource-rich and resource-limited settings.